The newsletter reports that the U.S. Food and Drug Administration has released a discussion paper on generative AI devices and that the agency has promised new guidance. The excerpt available in the source does not include the text of the discussion paper, specific regulatory proposals, timelines, or detailed recommendations from the FDA. Readers are informed of the existence of the discussion paper and the agency’s stated intent to provide further guidance, but the article does not provide operational or clinical specifics drawn from the FDA document.
Because the source excerpt is limited, no additional factual claims about the content of the FDA’s proposals — for example, definitions, classification approaches, premarket expectations, postmarket requirements, or examples of regulated functions — are reported here. Those details were not provided in the source material and therefore are not stated in this summary.
The newsletter indicates that it includes coverage of what occurred at Epic’s annual User Group Meeting (UGM). The available portion of the article announces that the author will catch readers up on "all the news about Epic we didn’t get to before the break last week," signaling planned reporting on Epic’s announcements and presentations.
However, the excerpt does not include the substantive content of Epic’s remarks, product updates, or any statements made at UGM. Specifics about new Epic features, AI tools, customer commitments, interoperability announcements, deployment timelines, or any demonstrated performance metrics are not contained in the provided source. Those specifics were not reported in the available excerpt and would be accessible only in the full STAT+ story.
The piece is presented as the web edition of STAT’s Health Tech newsletter. It is authored by Mario Aguilar, identified as Health Tech Correspondent, with the byline dated Aug. 25, 2026. The author’s contact email is provided in the excerpt, and the profile notes his reporting focus on FDA regulation of artificial intelligence, Medicare payment for health tech, the use of AI in clinical care, mental health chatbots, and consumer wearables.
The author opens with a conversational note about returning from vacation and asks readers what developments they have been watching. He also references seeing a JAMA paper asserting that AI alone may soon outperform AI working with doctors; that reference is mentioned in passing and the excerpt does not include additional details, citations, or takeaways from that JAMA publication.
The article is marked as exclusive to STAT+ subscribers. The excerpt contains a STAT+ subscriber prompt, subscription pricing options, and calls to subscribe or log in to read the remainder of the story. Multiple subscription tiers and sample pricing appear in the excerpt, including monthly and annual plan references; however, the presence of these price points serves only to indicate paywall status and access options and is not part of the article’s substantive reporting on FDA or Epic.
The newsletter explicitly instructs that to read the rest of the story, readers must subscribe to STAT+. As such, the publicly available excerpt provides an overview and context but omits the detailed reporting that appears under the paywall.
The excerpt situates the reported items within STAT’s broader Health Tech and policy coverage, linking to topics such as FDA, health tech newsletters, and several related STAT+ articles. It includes navigation elements and lists of popular and most-read pieces, some of which concern AI in health care, Medicare and regulatory developments, and other STAT+ exclusives. The excerpt also references STAT trackers and features relevant to health-technology monitoring.
The public portion of the newsletter contains visual assets and navigation but does not include primary-source quotes, regulatory citations, or detailed descriptions of either the FDA discussion paper or Epic’s UGM presentations. Those details were not reported in the source excerpt and would require access to the full STAT+ article.
This web edition serves as a brief framing note for readers about two topics: an FDA discussion paper on generative AI devices and events at Epic’s UGM. It confirms the existence of both items and signals that more detailed reporting is available to subscribers. It does not provide the substantive content, analysis, or direct quotations that would allow a clinical or technical reader to appraise regulatory implications or Epic’s product specifics.
For clinicians, regulators, and health-technology stakeholders seeking actionable detail — for example, how the FDA intends to classify generative AI tools, what compliance timelines might be proposed, or what Epic announced regarding AI integrations — the excerpt does not supply those facts. The source explicitly places the full reporting behind a STAT+ paywall; therefore, further details are not included in this summary because they were not reported in the provided source content.
This summary is based solely on the provided STAT News web excerpt titled "FDA promises new AI guidance, and what happened at Epic’s UGM," authored by Mario Aguilar and dated Aug. 25, 2026. The excerpt contains navigational elements, subscription prompts, related-coverage links, and the introductory portions of the newsletter. All factual statements above reflect only the information present in the supplied source excerpt; where substantive details were omitted in the source, this summary notes their absence rather than inferring or inventing content.